Full Title
A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, An Oral ALK Molecular Glue Degrader in Participants with Advanced ALK-Positive NSCLCPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Alexander Drilon’s office at 646-608-3758.
Protocol
26-016
Phase
Phase I/II (phases 1 and 2 combined)